More Post from the Author
- Johnny Lieberman of Harbor IT named Entrepreneur Of The Year 2026 New York finalist by EY US
- LITO Announces New Collaboration Bringing Exclusive Contemporary Artist Editions to Sotheby's Online Marketplace
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
Lumen Technologies to Attend Investor Conferences
DENVER, March 6, 2025 /PRNewswire/ --Lumen Technologies (NYSE: LUMN), will attend the following investor conferences:
- J.P. Morgan Global Technology, Media & Communications Conference on May 15.
- Barclays Leveraged Finance Conference, May 20-21.
When applicable, live webcast links to investor presentations will be available on the Lumen Investor Relations website.
About Lumen Technologies
Lumen is unleashing the world's digital potential. We ignite business growth by connecting people, data, and applications - quickly, securely, and effortlessly. As the trusted network for AI, Lumen uses the scale of our network to help companies realize AI's full potential. From metro connectivity to long-haul data transport to our edge cloud, security, managed service, anddigital platformcapabilities, we meet our customers' needs today and as they build for tomorrow.
For additional news and insights visitnews.lumen.com, LinkedIn:/lumentechnologies, Twitter:@lumentechco, Facebook:/lumentechnologies, Instagram:@lumentechnologiesand YouTube:/lumentechnologies.
SOURCE Lumen Technologies

More Post from the Author
- Johnny Lieberman of Harbor IT named Entrepreneur Of The Year 2026 New York finalist by EY US
- LITO Announces New Collaboration Bringing Exclusive Contemporary Artist Editions to Sotheby's Online Marketplace
- SIRUI Wins "Best of Show", Unveils New Cine Lenses at NAB Show 2026
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
